Literature DB >> 20434834

Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice.

Sara E Meyer1, Belinda E Peace, El Mustapha Bahassi, Gina M Kavanaugh, Purnima K Wagh, Susan B Robbins, Moying Yin, Susanne I Wells, Glendon M Zinser, Peter J Stambrook, Susan E Waltz.   

Abstract

The CHEK2 (Chk2 in mice) polymorphic variant, CHEK2*1100delC, leads to genomic instability and is associated with an increased risk for breast cancer. The Ron receptor tyrosine kinase is overexpressed in a large fraction of human breast cancers. Here, we asked whether the low penetrance Chk2*1100delC allele alters the tumorigenic efficacy of Ron in the development of mammary tumors in a mouse model. Our data demonstrate that Ron overexpression on a Chk2*1100delC background accelerates the development of mammary tumors, and shows that pathways mediated by a tyrosine kinase receptor and a regulator of the cell cycle can act to hasten tumorigenesis in vivo. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434834      PMCID: PMC2914152          DOI: 10.1016/j.canlet.2010.04.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  41 in total

1.  Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription.

Authors:  Hiroyuki Takai; Kazuhito Naka; Yuki Okada; Miho Watanabe; Naoki Harada; Shin'ichi Saito; Carl W Anderson; Ettore Appella; Makoto Nakanishi; Hiroshi Suzuki; Kazuo Nagashima; Hirofumi Sawa; Kyoji Ikeda; Noboru Motoyama
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

2.  Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Authors:  Hanne Meijers-Heijboer; Ans van den Ouweland; Jan Klijn; Marijke Wasielewski; Anja de Snoo; Rogier Oldenburg; Antoinette Hollestelle; Mark Houben; Ellen Crepin; Monique van Veghel-Plandsoen; Fons Elstrodt; Cornelia van Duijn; Carina Bartels; Carel Meijers; Mieke Schutte; Lesley McGuffog; Deborah Thompson; Douglas Easton; Nayanta Sodha; Sheila Seal; Rita Barfoot; Jon Mangion; Jenny Chang-Claude; Diana Eccles; Rosalind Eeles; D Gareth Evans; Richard Houlston; Victoria Murday; Steven Narod; Tamara Peretz; Julian Peto; Catherine Phelan; Hong Xiang Zhang; Csilla Szabo; Peter Devilee; David Goldgar; P Andrew Futreal; Katherine L Nathanson; Barbara Weber; Nazneen Rahman; Michael R Stratton
Journal:  Nat Genet       Date:  2002-04-22       Impact factor: 38.330

Review 3.  The Chk2 protein kinase.

Authors:  Jinwoo Ahn; Marshall Urist; Carol Prives
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

4.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Authors:  Rogier A Oldenburg; Karin Kroeze-Jansema; Jaennelle Kraan; Hans Morreau; Jan G M Klijn; Nicoline Hoogerbrugge; Marjolein J L Ligtenberg; Christi J van Asperen; Hans F A Vasen; Carel Meijers; Hanne Meijers-Heijboer; Truuske H de Bock; Cees J Cornelisse; Peter Devilee
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

5.  Identification of the ron gene product as the receptor for the human macrophage stimulating protein.

Authors:  M H Wang; C Ronsin; M C Gesnel; L Coupey; A Skeel; E J Leonard; R Breathnach
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

6.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

7.  A novel putative receptor protein tyrosine kinase of the met family.

Authors:  C Ronsin; F Muscatelli; M G Mattei; R Breathnach
Journal:  Oncogene       Date:  1993-05       Impact factor: 9.867

8.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

9.  Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner.

Authors:  Atsushi Hirao; Alison Cheung; Gordon Duncan; Pierre-Marie Girard; Andrew J Elia; Andrew Wakeham; Hitoshi Okada; Talin Sarkissian; Jorge A Wong; Takashi Sakai; Elisa De Stanchina; Robert G Bristow; Toshio Suda; Scott W Lowe; Penny A Jeggo; Stephen J Elledge; Tak W Mak
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.

Authors:  G Gaudino; A Follenzi; L Naldini; C Collesi; M Santoro; K A Gallo; P J Godowski; P M Comoglio
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

View more
  2 in total

1.  Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.

Authors:  Devikala Gurusamy; Sasha J Ruiz-Torres; Abby L Johnson; Dana A Smith; Susan E Waltz
Journal:  Mech Dev       Date:  2014-07-15       Impact factor: 1.882

Review 2.  Towards precision prevention: Technologies for identifying healthy individuals with high risk of disease.

Authors:  Zachary D Nagel; Bevin P Engelward; David J Brenner; Thomas J Begley; Robert W Sobol; Jason H Bielas; Peter J Stambrook; Qingyi Wei; Jennifer J Hu; Mary Beth Terry; Caroline Dilworth; Kimberly A McAllister; Les Reinlib; Leroy Worth; Daniel T Shaughnessy
Journal:  Mutat Res       Date:  2017-04-06       Impact factor: 2.433

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.